Related Experiment Videos
[Clinical studies on the choleretic agent Febuprol (author's transl)]
MMW, Munchener Medizinische Wochenschrift
|February 3, 1978
Summary
Febuprol, a choleretic agent, significantly improved symptoms in patients with gallbladder issues. The treatment also led to a notable reduction in serum cholesterol levels.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- Febuprol, a choleretic agent, demonstrated increased bile flow in prior acute experiments.
- Patients with cholecystopathic symptom complexes often experience debilitating gastrointestinal discomfort.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Febuprol in patients suffering from cholecystopathic symptoms.
- To assess the impact of Febuprol on serum cholesterol levels in this patient group.
Main Methods:
- A double-blind, cross-over therapeutic trial was conducted.
- Fifty patients with cholecystopathic symptoms received Febuprol for 14 days (3 capsules daily).
- Symptom improvement and serum cholesterol levels were monitored.
Main Results:
- Significant improvement in common symptoms such as post-meal nausea, abdominal pressure, bloating, and constipation was observed.
- A noteworthy reduction in serum cholesterol levels was recorded.
- The choleretic agent Febuprol proved effective in managing gallbladder-related symptoms.
Conclusions:
- Febuprol is an effective treatment for cholecystopathic symptom complexes.
- Febuprol may offer a dual benefit by alleviating gallbladder symptoms and reducing cholesterol levels.